Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles.

@article{Hegde2007DelineationOM,
  title={Delineation of molecular mechanisms of sensitivity to lapatinib in breast cancer cell lines using global gene expression profiles.},
  author={Priti S. Hegde and David Rusnak and Melissa A Bertiaux and Krystal J Alligood and Jay C. Strum and Robert C. Gagnon and Tona M. Gilmer},
  journal={Molecular cancer therapeutics},
  year={2007},
  volume={6 5},
  pages={1629-40}
}
Lapatinib (GW572016) is a small-molecule dual inhibitor of epidermal growth factor receptor (ErbB1) and ErbB2 receptor kinase activities currently in phase III clinical trials. We used phosphoprotein and microarray analyses to carry out targeted pathway studies of phosphorylation and gene expression changes in human breast cancer cell lines in the presence or absence of lapatinib. Studies were done in four breast cancer cell lines, two of which were responsive and two of which were… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 44 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 48 references

A phase I, open-label study of the safety, tolerability and pharmacokinetics of Lapatinib (GW572016) in combination with letrozole in cancer patients

  • Q Chu, L Goldstein, N Murray
  • Proc Am Soc Clin Oncol 2005;23:3001
  • 2005
1 Excerpt

Similar Papers

Loading similar papers…